Short-term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart FailureThe EVEREST Clinical Status Trials
Top Cited Papers
Open Access
- 28 March 2007
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 297 (12) , 1332-1343
- https://doi.org/10.1001/jama.297.12.1332
Abstract
Heart failure (HF) is a major international public health problem presenting significant medical and economic challenges. In the United States, HF has high prevalence (>5 million individuals), high incidence (550 000 new cases yearly), increasing hospitalization rates (400 000 in 1979 to >1 million in 2004), and exorbitant cost (estimated to exceed $33 billion in 2007).1 A considerable share of the burden of HF is accounted for by the acute HF syndromes (AHFS), defined as conditions with gradual or rapid changes in the signs and symptoms of HF that require urgent therapy.2 Patients hospitalized with AHFS have poor overall prognosis.3-8Keywords
This publication has 1 reference indexed in Scilit:
- Ultrafiltration Versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated Heart FailureJournal of the American College of Cardiology, 2007